Aurora Cannabis Inc Stock Price, News & Analysis

Aurora Cannabis (NASDAQ: ACB), a leading global medical cannabis company, has announced its upcoming first quarter 2026 earnings conference call. The event will take place on Wednesday, August 6, 2025, at 8:00 a.m. Eastern Time.

The company will release its Q1 2026 financial results before markets open on the same day. The conference call will be hosted by Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, and will include a question and answer session. Investors can access the webcast through Aurora's investor relations website.

Aurora Cannabis (NASDAQ: ACB) has reaffirmed its commitment to veterans through its Strains for Heroes initiative. The company donates 5% of net profits from Strains for Heroes products to veteran organizations annually, capped at C$200,000.

The program, launched in 2022, has developed five purpose-grown cannabis strains named by veterans: Valour, Courage, Honour, Esprit De Corps, and United Victory. Aurora collaborates with veteran communities to create custom strains based on their specific preferences and needs.

The company partners with various veteran organizations including Highway for Heroes, Post Traumatic Growth Association, and True Patriot Love, providing community outreach and charitable support.

Aurora Cannabis (NASDAQ: ACB) has achieved a significant regulatory milestone with its Brampton, Ontario distribution centre receiving EU-GMP certification. This marks Aurora's fourth EU-GMP certified facility within its global network, enhancing the company's international medical cannabis export capabilities.

The certification validates Aurora's compliance with the EudraLex rules for medicinal products in the European Union, demonstrating the company's commitment to maintaining high manufacturing standards and quality consistency. The Brampton facility will serve as a centralized hub for international distribution, optimizing the storage and distribution of medical cannabis products globally.

Aurora Cannabis (NASDAQ: ACB) has announced the filing and distribution of its management information circular for the upcoming annual general and special meeting of shareholders. The virtual meeting is scheduled for August 8, 2025, at 1:00 p.m. ET and will be conducted via live webcast.

The circular is now available on Aurora's website and SEDAR+, with materials being mailed to shareholders of record as of June 16, 2025. Shareholders are urged to vote by the deadline of August 6, 2025, at 1:00 p.m. ET. The board recommends voting FOR all director nominees and meeting resolutions.

Shareholders requiring assistance with voting can contact Laurel Hill Advisory Group, Aurora's proxy solicitation agent, through their toll-free number or email.

Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis compassionate pricing program in Canada by increasing the yearly income eligibility threshold from $40,000 to $60,000 CAD. This expansion makes Aurora's program the most inclusive medical cannabis pricing plan in Canada, potentially benefiting over half of the country's adult population.

The company has also introduced new medical cannabis products including Aurora | Mediora Minis (Cannatonic CBD Flower), Daily Special | Sativa J's (THC Pre-Rolls), and WMMC | Seasonal Stash Petro Biscuit (THC Flower). Aurora continues to provide resources for seniors, pediatric patients, veterans, and first responders through their medical cannabis program.

Aurora Cannabis (NASDAQ: ACB) has announced the launch of two new high-potency medical cannabis products in Poland. The company will introduce Farm Gas (27% THC) on June 30 and Sourdough (29% THC) in early August 2025, representing the highest potency medical cannabis products in the Polish market.

Both proprietary cultivars are grown in Aurora's Canadian GACP and EU-GMP facilities. Farm Gas, bred from Sour Diesel and GMO genetics, features a unique terpene profile with limonene and caryophyllene. Sourdough, derived from Cake and Diesel genetics, offers distinct sour and gasoline notes with high THC content.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) has issued a statement addressing two false articles published on Investing.com. The first article falsely claimed Aurora agreed to acquire New Zealand's MedLeaf Therapeutics, while the second incorrectly stated the company entered a strategic partnership with MediPharm GmbH for cannabis distribution in Germany and EU markets. Aurora explicitly denies both claims, stating it has not engaged in discussions with either company regarding acquisitions or partnerships. The articles were reportedly generated with AI support and reviewed by an editor. Aurora has launched an investigation into these false publications and emphasizes that any material corporate transactions will be announced directly by the company. The company confirms it holds no material non-public information and warns investors against relying on Investing.com for Aurora-related news.

Aurora Cannabis (NASDAQ: ACB) has officially denied rumors regarding its alleged acquisition of New Zealand-based MedLeaf Therapeutics. The company explicitly stated it has not entered into any agreement with MedLeaf Therapeutics, nor has it engaged in any discussions about a potential business combination. The statement comes in response to incorrect information published on a news website. Aurora also noted that it had filed its Q4 and fiscal year 2025 financial statements and management's discussion and analysis earlier that day, with all relevant information available on the company's website and regulatory platforms SEDAR+ and EDGAR.

Aurora Cannabis (ACB) reported strong fiscal year 2025 results with record annual global medical cannabis net revenue of $244.4M, up 39% YoY. Q4 2025 delivered total net revenue of $90.5M, a 34% increase YoY, driven by 48% growth in medical cannabis and 32% growth in plant propagation. The company achieved record adjusted EBITDA of $49.7M (261% YoY growth) and generated positive annual free cash flow of $9.9M. Medical cannabis represented 75% of Q4 revenue at $67.8M, with international revenue doubling to 61% of global medical cannabis sales. The company maintains a strong balance sheet with $185.3M cash and a debt-free cannabis business. Q4 adjusted gross margin reached 62%, with medical cannabis margins at 70%. Consumer cannabis revenue declined 20% to $8.2M as the company prioritized higher-margin medical sales.